Back to Journals » Drug Design, Development and Therapy » Volume 17 » Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes
Please verify you are not a robot.